


1. The first step is to identify the patient's airway and ensure that it is patent. This is done by performing a physical examination and using a stethoscope to listen for breath sounds.

2. The next step is to perform a thorough physical examination of the patient's neck and chest. This includes palpating the thyroid gland, trachea, and lungs.

3. The final step is to perform a chest X-ray to rule out any underlying lung disease.



1. The first step is to identify the patient's airway and ensure that it is patent. This is done by performing a physical examination and using a stethoscope to listen for breath sounds.

[illegible]

[illegible][illegible]

- [illegible]

[illegible][illegible]

● 2019年10月，国家药品监督管理局批准了首个国产GLP-1受体激动剂司美格鲁肽注射液上市。该药用于治疗2型糖尿病，并能显著降低血糖、改善胰岛素敏感性、减轻体重。司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。

- 司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。
- 司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。
- 司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。
- 司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。
- 司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。
- 司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。
- 司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。

司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。

司美格鲁肽注射液 GLP-1 受体激动剂


司美格鲁肽注射液 GLP-1 受体激动剂，用于治疗2型糖尿病，并能显著降低血糖、改善胰岛素敏感性、减轻体重。司美格鲁肽注射液在临床试验中表现出良好的安全性和有效性，且不良反应发生率较低。目前，该药已在多家医院开始使用，患者反响积极。

[illegible]

- **Clear Liquid Diet** (www.mskcc.org/cancer-care/patient-education/clear-liquid-diet) **is a diet that includes only clear liquids.**
- **Clear Liquid Diet** **includes:** 8 **ounces of clear liquids, such as water, broth, clear juice, and clear tea, are recommended.**

■■■■ ■■■■■ ■■■, *Eating and Drinking Before Your Surgery or Procedure When Taking GLP-1 Medicines* (www.mskcc.org/cancer-care/patient-education/eating-and-drinking-before-your-surgery-or-procedure-when-taking-glp-1-medicines)
■■■■■■■ |

GLP-1 受体激动剂在糖尿病治疗中具有重要地位。其通过模拟内源性 GLP-1 的作用，刺激胰岛 β 细胞分泌胰岛素，同时抑制胰高血糖素分泌，从而降低血糖。此外，GLP-1 受体激动剂还能延缓胃排空、增加饱腹感，有助于体重减轻。目前，已有多种 GLP-1 受体激动剂上市，如艾塞那肽、利拉鲁肽、司美格鲁肽等。这些药物在临床应用中显示出良好的疗效和安全性，已成为糖尿病治疗的一线选择。

-  (®,
®, ®)
- 
(®)

■■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■

2019年12月31日，公司资产总额为1,000,000,000.00元，负债总额为500,000,000.00元，所有者权益总额为500,000,000.00元。

MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#).

MSK MyChart

MSK MyChart ([mskmychart.mskcc.org](#)) MSK's secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#). MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#).

MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#). MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#).

MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#). MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#).







MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#). MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#).

MSK MyChart is a secure online tool that lets you manage your health care. You can view your medical records, schedule appointments, and more. For more information, visit [mskmychart.mskcc.org](#).

[illegible]

- **Согласно** **статье 109 Конституции Российской Федерации**, **законодательная власть принадлежит** **Федеральному Собранию Российской Федерации и законодательным органам субъектов Российской Федерации**.
В соответствии с Конституцией Российской Федерации, **законодательные акты принимаются на уровне субъекта Российской Федерации** (статья 78 Конституции Российской Федерации), **а также на уровне Российской Федерации** (статья 107 Конституции Российской Федерации).
- **Согласно статье 106 Конституции Российской Федерации** **МСК** **является органом государственной власти субъекта Российской Федерации**.
Согласно **статье 106 Конституции Российской Федерации**, **органы государственной власти субъекта Российской Федерации** **осуществляют свои функции в соответствии с Конституцией Российской Федерации и законами субъекта Российской Федерации**.
Согласно **статье 106 Конституции Российской Федерации**, **органы государственной власти субъекта Российской Федерации** **осуществляют свои функции в соответствии с Конституцией Российской Федерации и законами субъекта Российской Федерации**.
- **Согласно статье 106 Конституции Российской Федерации** **МСК является органом государственной власти субъекта Российской Федерации**.
Согласно **статье 106 Конституции Российской Федерации**, **органы государственной власти субъекта Российской Федерации** **осуществляют свои функции в соответствии с Конституцией Российской Федерации и законами субъекта Российской Федерации**.

[illegible]

-  (EKG) 
 ()  |
-  - |
-  |

When you are in a difficult situation, it is important to know when to ask for help. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break.

When you are in a difficult situation, it is important to know when to ask for help. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break.

When you are in a difficult situation, it is important to know when to ask for help. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break.

When you are in a difficult situation, it is important to know when to ask for help.



When you are in a difficult situation, it is important to know when to ask for help. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break.

For more information, visit www.mskcc.org/cancer-care/patient-education/guide-caregivers. *A Guide for Caregivers* (www.mskcc.org/cancer-care/patient-education/guide-caregivers)

When you are in a difficult situation, it is important to know when to ask for help.

When you are in a difficult situation, it is important to know when to ask for help. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break.

When you are in a difficult situation, it is important to know when to ask for help. You may not be able to do everything on your own, and that is okay. It is important to know when to ask for help and when to take a break.

2020年12月31日，本公司不存在应计提减值准备的金融资产，因此未计提减值准备。

1. The first part of the document is a header section containing the title "THE HISTORY OF THE UNITED STATES" and the author "BY JAMES M. SMITH, M.D., F.R.S.E." followed by a list of contents.

[illegible]

■■■■ ■■■■■■■■■■ ■■■■ ■■■, ■■■ *How To Check if a Medicine or Supplement Has Aspirin, Other NSAIDs, Vitamin E, or Fish Oil* (www.mskcc.org/cancer-care/patient-education/common-medications-containing-aspirin-and-other-nonsteroidal-anti-inflammatory-drugs-nsaids) ■■■■■■ |

2020年12月，中国疾病预防控制中心，中国疾病预防控制中心
 2020年12月，中国疾病预防控制中心，中国疾病预防控制中心
 2020年12月，中国疾病预防控制中心，中国疾病预防控制中心

Aspirin, NSAIDs, and other blood-thinning medications can increase the risk of bleeding. If you are taking any of these medications, you should talk to your doctor before taking any herbal remedies. Some herbal remedies can also interact with your medications. For example, ginkgo biloba can increase the risk of bleeding when taken with aspirin or NSAIDs. St. John's wort can interfere with many medications, including chemotherapy. Always tell your doctor about all the herbs and supplements you are taking.

For more information on herbal remedies and cancer treatment, visit www.mskcc.org/cancer-care/patient-education/herbal-remedies-and-treatment.

2. NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) are commonly used to relieve pain and reduce inflammation. Examples include ibuprofen (Advil, Motrin) and naproxen (Aleve). NSAIDs can increase the risk of bleeding, especially when taken with aspirin or other blood-thinning medications. If you are taking NSAIDs, you should avoid taking aspirin or other blood-thinning medications. Always talk to your doctor before taking any NSAIDs.

How To Check if a Medicine or Supplement Has Aspirin, Other NSAIDs, Vitamin E, or Fish Oil (www.mskcc.org/cancer-care/patient-education/common-medications-containing-aspirin-and-other-nonsteroidal-anti-inflammatory-drugs-nsaids)

1. Check the label. Many over-the-counter medications and supplements have their ingredients listed on the label. Look for aspirin, NSAIDs, vitamin E, or fish oil. If you find any of these ingredients, you should avoid taking the medication or supplement. 2. Ask your doctor. If you are unsure if a medication or supplement contains any of these ingredients, ask your doctor. They can help you check the label and provide advice on whether you should take it. 3. Call the manufacturer. If you cannot find the ingredients on the label, you can call the manufacturer's toll-free number. For example, you can call 212-639-5014 for more information.

For more information on common medications containing aspirin and other NSAIDs, visit www.mskcc.org/cancer-care/patient-education/common-medications-containing-aspirin-and-other-nonsteroidal-anti-inflammatory-drugs-nsaids.

MSK is a leading cancer center in New York City. We are committed to providing the best care for our patients. For more information, please visit our website at www.mskcc.org.

MSK is a leading cancer center in New York City. We are committed to providing the best care for our patients. For more information, please visit our website at www.mskcc.org.

- MSK is a leading cancer center in New York City. We are committed to providing the best care for our patients. For more information, please visit our website at www.mskcc.org. (PSC) 1275 Broadway, New York, NY 10065. For more information, please visit our website at www.mskcc.org. (PSC) 1275 Broadway, New York, NY 10065. For more information, please visit our website at www.mskcc.org.
- MSK is a leading cancer center in New York City. We are committed to providing the best care for our patients. For more information, please visit our website at www.mskcc.org. (PSC) 1275 Broadway, New York, NY 10065. For more information, please visit our website at www.mskcc.org.

MSK is a leading cancer center in New York City. We are committed to providing the best care for our patients. For more information, please visit our website at www.mskcc.org.

MSK is a leading cancer center in New York City. We are committed to providing the best care for our patients. For more information, please visit our website at www.mskcc.org.

MSK is a leading cancer center in New York City. We are committed to providing the best care for our patients. For more information, please visit our website at www.mskcc.org. *Eating and Drinking Before Your Surgery or Procedure When Taking GLP-1 Medicines* (www.mskcc.org/cancer-care/patient-education/eating-and-drinking-before-your-surgery-or-procedure-when-taking-glp-1-medicines)



Do not eat or drink anything (12 hours) before your surgery or procedure. This includes water, clear liquids, and solid foods. You may take your usual medications with a small sip of water.

Do not eat or drink anything (12 hours) before your surgery or procedure. This includes water, clear liquids, and solid foods. You may take your usual medications with a small sip of water. If you are taking GLP-1 medicines, you may need to stop them before surgery. Talk to your doctor about when to stop them.

Do not eat or drink anything (12 hours) before your surgery or procedure. This includes water, clear liquids, and solid foods. You may take your usual medications with a small sip of water.

Important: Do not eat or drink anything (12 hours) before your surgery or procedure. This includes water, clear liquids, and solid foods. You may take your usual medications with a small sip of water. If you are taking GLP-1 medicines, you may need to stop them before surgery. Talk to your doctor about when to stop them. *Eating and Drinking Before Your Surgery or Procedure When Taking GLP-1 Medicines* (www.mskcc.org/cancer-care/patient-education/eating-and-drinking-before-your-surgery-or-procedure-when-taking-glp-1-medicines)

Do not eat or drink anything (12 hours) before your surgery or procedure. This includes water, clear liquids, and solid foods. You may take your usual medications with a small sip of water. If you are taking GLP-1 medicines, you may need to stop them before surgery. Talk to your doctor about when to stop them.

- Do not eat or drink anything (12 hours) before your surgery or procedure. This includes water, clear liquids, and solid foods. You may take your usual medications with a small sip of water.
- If you are taking GLP-1 medicines, you may need to stop them before surgery. Talk to your doctor about when to stop them.
- Do not eat or drink anything (12 hours) before your surgery or procedure. This includes water, clear liquids, and solid foods. You may take your usual medications with a small sip of water.

- 2020 年 1 月 1 日起，所有在北京市行政区域内从事经营活动的餐饮服务提供者，应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。
- 餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。
- 餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。

餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。

餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。



餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。

餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。

餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。

餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。餐饮服务提供者应当按照《北京市生活垃圾管理条例》的要求，将餐厨垃圾单独分类投放至指定的收集容器，不得随意倾倒、混装和丢弃。

- [illegible]

■■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ ■■■■

1980年，在“六四”事件后，中国开始实施改革开放政策，经济迅速发展，人民生活水平显著提高。这一时期，中国在国际事务中逐渐发挥越来越重要的作用，成为世界大国之一。随着综合国力的增强，中国积极参与全球治理，推动构建人类命运共同体。进入新时代以来，中国坚持高质量发展，全面推进乡村振兴，实现第一个百年奋斗目标，开启了全面建设社会主义现代化国家新征程。当前，中国正朝着第二个百年奋斗目标迈进，为实现中华民族伟大复兴的中国梦而努力奋斗。

1. 本報告係根據「證券管理條例」及「證券發行人財務報告編製準則」之規定，由本公司董事會編製，並經會計師查核簽證，其內容與事實相符，並無虛偽或隱匿任何重要事項，且經本公司董事會決議通過，爰將本報告刊登於公開資訊觀開系統，以供各界人士參考。

1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2

■■■■■■■■ ■■■■■■ IV ■■■■ ■■■■■■ ■■■■ ■■■■■■ ■■■■■■
■■■■■ |

☐ ☐ ☐ ☐ ☐ ☐
☐ ☐ ☐ ☐ ☐
☐ ☐ ☐ ☐ ☐

本報告書は、我が国の経済成長と環境保護の両立を目指すための政策提言を目的として作成された。まず、持続可能な開発目標（SDGs）の観点から、資源の有効な利用と気候変動への対応が重要な課題であることが示されている。次に、政府、企業、市民社会の各主体が果たすべき役割について検討する。特に、企業の社会的責任（CSR）の強化と、消費者意識の高まりが期待される。また、教育を通じた環境意識の醸成も不可欠である。最後に、具体的な政策提案として、再生可能エネルギーの普及促進と、循環型経済の実現に向けた取り組みを挙げる。以上により、持続可能な未来を実現するための道筋を示すことができた。

1. 本報告係根據「證券交易法」及「證券發行人財務報告編製準則」之規定，由本公司董事會決議通過，並經會計師查核簽證後，向主管機關申報在案。

[illegible]

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044

[REDACTED]-[REDACTED] [REDACTED] [REDACTED] (PACU)

「『このように、iPadの画面を操作する際には、指で直接触るのではなく、専用のペンを使用する必要があります。』」

「また、このペンには、3つのボタンがあり、それぞれに異なる機能が割り当てられています。例えば、一番上のボタンは、画面のスクリーンショットを撮るために使われます。また、一番下のボタンは、画面の拡大・縮小のために使われます。そして、中央のボタンは、画面の回転のために使われます。このように、このペンには、非常に便利な機能が搭載されています。ぜひ、このペンを使って、iPadの画面を操作してみてください。きっと、今までとは違う感覚で操作できると思います。」

「このように、このペンには、非常に便利な機能が搭載されています。」

「また、このペンには、非常に便利な機能が搭載されています。例えば、一番上のボタンは、画面のスクリーンショットを撮るために使われます。また、一番下のボタンは、画面の拡大・縮小のために使われます。そして、中央のボタンは、画面の回転のために使われます。このように、このペンには、非常に便利な機能が搭載されています。ぜひ、このペンを使って、iPadの画面を操作してみてください。きっと、今までとは違う感覚で操作できると思います。」

「また、このペンには、非常に便利な機能が搭載されています。例えば、一番上のボタンは、画面のスクリーンショットを撮るために使われます。また、一番下のボタンは、画面の拡大・縮小のために使われます。そして、中央のボタンは、画面の回転のために使われます。このように、このペンには、非常に便利な機能が搭載されています。ぜひ、このペンを使って、iPadの画面を操作してみてください。きっと、今までとは違う感覚で操作できると思います。」

「また、このペンには、非常に便利な機能が搭載されています。例えば、一番上のボタンは、画面のスクリーンショットを撮るために使われます。また、一番下のボタンは、画面の拡大・縮小のために使われます。そして、中央のボタンは、画面の回転のために使われます。このように、このペンには、非常に便利な機能が搭載されています。ぜひ、このペンを使って、iPadの画面を操作してみてください。きっと、今までとは違う感覚で操作できると思います。」

■■■■■-■■■■■ ■■■■ ■■■■ ■■■■ ■■■■

[illegible]

■■■■ ■■■■ ■■■■ ■■■■

2000 年 12 月 20 日，
 2000 年 12 月 20 日 NG 2000 年 12 月 20 日 | 2000 年 12 月 20 日
 '2000 年 12 月 20 日 8 2000 年 12 月 20 日 | 2000 年 12 月 20 日
 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日，
 2000 年 12 月 20 日， 2000 年 12 月 20 日 2000 年 12 月 20 日， 2000
 2000 年 12 月 20 日 NG 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日
 '2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日 | 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日
 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日
 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日 2000 年 12 月 20 日
 2000 年 12 月 20 日， 2000 年 12 月 20 日-2000 年 12 月 20 日 2000 年 12 月 20 日 |

NG

2020 2021 2022 2023 NG 2024 2025 2026 2027 2028 2029 ,
 2030 2031 2032 2033 2034 2035 2036 2037 2038 |
 2039 2040 2041 -2042 2043 2044 2045 (2046
 2047 2048 2049 2050), 2051 2052 2053 2054 2055 2056 ,
 2057 2058 2059 2060 2061 2062 2063 2064 2065 |
 2066 2067 2068 2069 2070 2071 2072 , 2073 2074 , 2075
 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086

2019 年 12 月 31 日，本公司应收账款账面余额为 1,000.00 万元，坏账准备余额为 100.00 万元。

2019 年 12 月 31 日，本公司应收账款 (HME) 账面余额为 1,000.00 万元，坏账准备余额为 100.00 万元。

2019 年 12 月 31 日，本公司应收账款 (HME) 账面余额为 1,000.00 万元，坏账准备余额为 100.00 万元。

HME 2019 年 12 月 31 日账面余额为 1,000.00 万元，坏账准备余额为 100.00 万元。

2019 年 12 月 31 日，本公司应收账款 (HME) 账面余额为 1,000.00 万元，坏账准备余额为 100.00 万元。

2019 年 12 月 31 日，本公司应收账款 (HME) 账面余额为 1,000.00 万元，坏账准备余额为 100.00 万元。

[illegible]

28/65

በዚህ ሪፖርት ላይ፣ የጥናቱ ዓላማና ዋና ዓላማዎች በግልጽ ተገልጾባል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ሪፖርቱ የሚያስፈልገውን መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል።

በጥናቱ ውስጥ፣ የሚያስፈልገውን መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል።

የጥናቱ ዓላማ

የጥናቱ ዓላማ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል።

የጥናቱ ዓላማ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል።

የጥናቱ ዓላማ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል።

የጥናቱ ዓላማ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል። ጥናቱ የሚመለከተው የህዝብ ጥምረት ስለሆነ፣ ለዚህ ሪፖርት ላይ የተካተተው መረጃ በጥንቃቄ ተሰብሮና ተፈቃኝነቱ ተረጋግጧል።

...
...
...
...
...
...
...

...
...
...
...
...
...
...
...
...
...
...

...

...
...
...
...
...
...

... 11
...
...
...
...
...
...
...
...
...
...

...
...

MSK's Recovery Tracker, *Common Questions About MSK's Recovery Tracker*
(www.mskcc.org/cancer-care/patient-education/mymsk-recovery-tracker)
MSK's Recovery Tracker

What is MSK's Recovery Tracker?

MSK's Recovery Tracker is a tool that helps patients and families understand what to expect during and after cancer treatment. It provides information on the most common side effects of cancer treatment, such as fatigue, hair loss, and changes in appearance. It also provides information on how to manage these side effects and when to seek medical attention. MSK's Recovery Tracker is available in both English and Spanish. It is a free, online tool that can be accessed at any time. It is a valuable resource for patients and families who are undergoing cancer treatment. It provides a comprehensive overview of the most common side effects of cancer treatment, such as fatigue, hair loss, and changes in appearance. It also provides information on how to manage these side effects and when to seek medical attention. MSK's Recovery Tracker is available in both English and Spanish. It is a free, online tool that can be accessed at any time. It is a valuable resource for patients and families who are undergoing cancer treatment.

MSK's Recovery Tracker is a tool that helps patients and families understand what to expect during and after cancer treatment. It provides information on the most common side effects of cancer treatment, such as fatigue, hair loss, and changes in appearance. It also provides information on how to manage these side effects and when to seek medical attention. MSK's Recovery Tracker is available in both English and Spanish. It is a free, online tool that can be accessed at any time. It is a valuable resource for patients and families who are undergoing cancer treatment.

- MSK's Recovery Tracker is a tool that helps patients and families understand what to expect during and after cancer treatment. It provides information on the most common side effects of cancer treatment, such as fatigue, hair loss, and changes in appearance. It also provides information on how to manage these side effects and when to seek medical attention. MSK's Recovery Tracker is available in both English and Spanish. It is a free, online tool that can be accessed at any time. It is a valuable resource for patients and families who are undergoing cancer treatment.
- MSK's Recovery Tracker is a tool that helps patients and families understand what to expect during and after cancer treatment. It provides information on the most common side effects of cancer treatment, such as fatigue, hair loss, and changes in appearance. It also provides information on how to manage these side effects and when to seek medical attention. MSK's Recovery Tracker is available in both English and Spanish. It is a free, online tool that can be accessed at any time. It is a valuable resource for patients and families who are undergoing cancer treatment.
- MSK's Recovery Tracker is a tool that helps patients and families understand what to expect during and after cancer treatment. It provides information on the most common side effects of cancer treatment, such as fatigue, hair loss, and changes in appearance. It also provides information on how to manage these side effects and when to seek medical attention. MSK's Recovery Tracker is available in both English and Spanish. It is a free, online tool that can be accessed at any time. It is a valuable resource for patients and families who are undergoing cancer treatment.
- MSK's Recovery Tracker is a tool that helps patients and families understand what to expect during and after cancer treatment. It provides information on the most common side effects of cancer treatment, such as fatigue, hair loss, and changes in appearance. It also provides information on how to manage these side effects and when to seek medical attention. MSK's Recovery Tracker is available in both English and Spanish. It is a free, online tool that can be accessed at any time. It is a valuable resource for patients and families who are undergoing cancer treatment.

- 2019 年 12 月 31 日，公司 2019 年度利润分配方案为：以 2019 年 12 月 31 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），共计派发现金股利 500,000,000.00 元，已于 2020 年 3 月 10 日实施完毕。
 - 2020 年 6 月 30 日，公司 2020 年半年度利润分配方案为：以 2020 年 6 月 30 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），共计派发现金股利 500,000,000.00 元，已于 2020 年 9 月 10 日实施完毕。
 - 2020 年 12 月 31 日，公司 2020 年度利润分配方案为：以 2020 年 12 月 31 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），共计派发现金股利 500,000,000.00 元，已于 2021 年 3 月 10 日实施完毕。
- 2021 年 12 月 31 日，公司 2021 年度利润分配方案为：以 2021 年 12 月 31 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），共计派发现金股利 500,000,000.00 元，已于 2022 年 3 月 10 日实施完毕。
- 2022 年 12 月 31 日，公司 2022 年度利润分配方案为：以 2022 年 12 月 31 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），共计派发现金股利 500,000,000.00 元，已于 2023 年 3 月 10 日实施完毕。

2023 年 12 月 31 日，公司 2023 年度利润分配方案为：以 2023 年 12 月 31 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），共计派发现金股利 500,000,000.00 元，已于 2024 年 3 月 10 日实施完毕。

□□□□ □□□□□□ □□□□ □□□□□□ □□□ |

□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□ □□□ □□□□□□□ □□□□□□□□
□□□□□□ □□□

1. □□□□□□□ □□□□□□□□ □□□□□□□□ □□□□ | □□□□□□□□ □□□□
□□□□□□□:

- □□□□□□□□ □□□□□□□□ □□□□□ □□□□□□ □□□□□□
- □□□□ □□□□□□ □□□□□□□□ (□□□□□□ □□□□)
- □□□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□
- □□□□ □□□□□□□□
- □□□□ □□□□□ □□□□ □□□□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□
(□□□□□ □□□□□□ □□ □□□□□ □□□□□)
- □□□□□ □□□□ □□□□□□ □□□□□ □□□□ (□□□□□□ □□□□□□□
□□□□□□□ □□□□□ □□□□□)

2. □□□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□□□□ □□□□□ |

3. □□□□□□ □□□□□□□ □□□□ □□□□□□ □□□□□□ □□ □□□□□□□□
□□□□□□□□ □□□□ □□□□□ |

4. □□□□□□□ □□□□ □□ □□□□□□□ □□□□□ □□ □□□□□□ □□□□□
□□□□□□□□□□□□□ □□□□□□ □□ □□□□□□□□□ □□□□□□ □□□□
□□□□□ |

5. □□□□□□ □□□□□□ □□□□□ □□□□ | (□□□ □□□□□□ □□□□□□□ □□□□□
□□□, □□□□ □□□□□□ □□□□□ □□□□□ □□□ □□ □□□□□ □□□□□
□□□□□□□□ □□□□ □□□□ □□□□□ □□□□□□□□ □□□□□□□) | □□□□□□ □□□□
□□□□□ □□ □□□□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□□□
□□□□□□ □□□□□□□ □□□□ □□ □□□□□□ |

6. □□□□□ □□□□ □□□□ □□□□□□□□ □□□□ □□□□□ □□□□□□ □□□
□□□□□□ □□□□ □□□□□ |

7. □□□□□□ □□□□□□□ □□□□ □□□□ □□ □□□□□ | □□□□□□ □□□□□
□□□□□□ □□□□□ □□□□□ 3 □□□□□ 5 □□□□□ (8 □□□□□ 13 □□□□□□□□□□□□)
□□□□□ (□□□□□□□ 4 □□□□□□□) |



- 36/65


11. 在《说文解字》中，「解」字从「角」从「刀」，「解」字的本义是「解角」，即「解牛」。
12. 在《说文解字》中，「解」字从「角」从「刀」，「解」字的本义是「解角」，即「解牛」。

在《说文解字》中，「解」字的本义是「解角」，即「解牛」。

1. 在《说文解字》中，「解」字从「角」从「刀」，「解」字的本义是「解角」，即「解牛」。
2. 在《说文解字》中，「解」字从「角」从「刀」，「解」字的本义是「解角」，即「解牛」。
3. 在《说文解字》中，「解」字从「角」从「刀」，「解」字的本义是「解角」，即「解牛」。
4. 在《说文解字》中，「解」字从「角」从「刀」，「解」字的本义是「解角」，即「解牛」。

在《说文解字》中，「解」字的本义是「解角」，即「解牛」。

在《说文解字》中，「解」字的本义是「解角」，即「解牛」。




5. [REDACTED]

7. [REDACTED], [REDACTED]
[REDACTED] | [REDACTED]
[REDACTED] | ([REDACTED]
[REDACTED], [REDACTED]
[REDACTED]) |
8. [REDACTED]
[REDACTED] |
9. [REDACTED]
([REDACTED]) [REDACTED]-[REDACTED]
[REDACTED]-[REDACTED] |
10. [REDACTED]
[REDACTED] |
11. [REDACTED] |
12. [REDACTED]
[REDACTED] (6 [REDACTED]) |



14.

- The following table shows the number of people who have been
 convicted of a crime in the last five years, broken down by
 age group and gender. The data is based on a survey of
 1,000 people.




7.

3 5

1. **Введение**
 2. **Цели и задачи**
 3. **Методология**
 4. **Результаты**
 5. **Заключение**
 6. **Список литературы**
 7. **Приложение**
 8. **Сводная таблица**
 9. **Выводы**
 10. **Рекомендации**
 11. **Заключение**
 12. **Список литературы**
 13. **Приложение**
 14. **Сводная таблица**
 15. **Выводы**
 16. **Рекомендации**
 17. **Заключение**
 18. **Список литературы**
 19. **Приложение**
 20. **Сводная таблица**
 21. **Выводы**
 22. **Рекомендации**
 23. **Заключение**
 24. **Список литературы**
 25. **Приложение**
 26. **Сводная таблица**
 27. **Выводы**
 28. **Рекомендации**
 29. **Заключение**
 30. **Список литературы**
 31. **Приложение**
 32. **Сводная таблица**
 33. **Выводы**
 34. **Рекомендации**
 35. **Заключение**
 36. **Список литературы**
 37. **Приложение**
 38. **Сводная таблица**
 39. **Выводы**
 40. **Рекомендации**
 41. **Заключение**
 42. **Список литературы**
 43. **Приложение**
 44. **Сводная таблица**
 45. **Выводы**
 46. **Рекомендации**
 47. **Заключение**
 48. **Список литературы**
 49. **Приложение**
 50. **Сводная таблица**
 51. **Выводы**
 52. **Рекомендации**
 53. **Заключение**
 54. **Список литературы**
 55. **Приложение**
 56. **Сводная таблица**
 57. **Выводы**
 58. **Рекомендации**
 59. **Заключение**
 60. **Список литературы**
 61. **Приложение**
 62. **Сводная таблица**
 63. **Выводы**
 64. **Рекомендации**
 65. **Заключение**
 66. **Список литературы**
 67. **Приложение**
 68. **Сводная таблица**
 69. **Выводы**
 70. **Рекомендации**
 71. **Заключение**
 72. **Список литературы**
 73. **Приложение**
 74. **Сводная таблица**
 75. **Выводы**
 76. **Рекомендации**
 77. **Заключение**
 78. **Список литературы**
 79. **Приложение**
 80. **Сводная таблица**
 81. **Выводы**
 82. **Рекомендации**
 83. **Заключение**
 84. **Список литературы**
 85. **Приложение**
 86. **Сводная таблица**
 87. **Выводы**
 88. **Рекомендации**
 89. **Заключение**
 90. **Список литературы**
 91. **Приложение**
 92. **Сводная таблица**
 93. **Выводы**
 94. **Рекомендации**
 95. **Заключение**
 96. **Список литературы**
 97. **Приложение**
 98. **Сводная таблица**
 99. **Выводы**
 100. **Рекомендации**
 101. **Заключение**
 102. **Список литературы**
 103. **Приложение**
 104. **Сводная таблица**
 105. **Выводы**
 106. **Рекомендации**
 107. **Заключение**
 108. **Список литературы**
 109. **Приложение**
 110. **Сводная таблица**
 111. **Выводы**
 112. **Рекомендации**
 113. **Заключение**
 114. **Список литературы**
 115. **Приложение**
 116. **Сводная таблица**
 117. **Выводы**
 118. **Рекомендации**
 119. **Заключение**
 120. **Список литературы**
 121. **Приложение**
 122. **Сводная таблица**
 123. **Выводы**
 124. **Рекомендации**
 125. **Заключение**
 126. **Список литературы**
 127. **Приложение**
 128. **Сводная таблица**
 129. **Выводы**
 130. **Рекомендации**
 131. **Заключение**
 132. **Список литературы**
 133. **Приложение**
 134. **Сводная таблица**
 135. **Выводы**
 136. **Рекомендации**
 137. **Заключение**
 138. **Список литературы**
 139. **Приложение**
 140. **Сводная таблица**
 141. **Выводы**
 142. **Рекомендации**
 143. **Заключение**
 144. **Список литературы**
 145. **Приложение**
 146. **Сводная таблица**
 147. **Выводы**
 148. **Рекомендации**
 149. **Заключение**
 150. **Список литературы**
 151. **Приложение**
 152. **Сводная таблица**
 153. **Выводы**
 154. **Рекомендации**
 155. **Заключение**
 156. **Список литературы**
 157. **Приложение**
 158. **Сводная таблица**
 159. **Выводы**
 160. **Рекомендации**
 161. **Заключение**
 162. **Список литературы**
 163. **Приложение**
 164. **Сводная таблица**
 165. **Выводы**
 166. **Рекомендации**
 167. **Заключение**
 168. **Список литературы**
 169. **Приложение**
 170. **Сводная таблица**
 171. **Выводы**
 172. **Рекомендации**
 173. **Заключение**
 174. **Список литературы**
 175. **Приложение**
 176. **Сводная таблица**
 177. **Выводы**
 178. **Рекомендации**
 179. **Заключение**
 180. **Список литературы**
 181. **Приложение**
 182. **Сводная таблица**
 183. **Выводы**
 184. **Рекомендации**
 185. **Заключение**
 186. **Список литературы**
 187. **Приложение**
 188. **Сводная таблица**
 189. **Выводы**
 190. **Рекомендации**
 191. **Заключение**
 192. **Список литературы**
 193. **Приложение**
 194. **Сводная таблица**
 195. **Выводы**
 196. **Рекомендации**
 197. **Заключение**
 198. **Список литературы**
 199. **Приложение**
 200. **Сводная таблица**
 201. **Выводы**
 202. **Рекомендации**
 203. **Заключение**
 204. **Список литературы**
 205. **Приложение**
 206. **Сводная таблица**
 207. **Выводы**
 208. **Рекомендации**
 209. **Заключение**
 210. **Список литературы**
 211. **Приложение**
 212. **Сводная таблица**
 213. **Выводы**
 214. **Рекомендации**
 215. **Заключение**
 216. **Список литературы**
 217. **Приложение**
 218. **Сводная таблица**
 219. **Выводы**
 220. **Рекомендации**
 221. **Заключение**
 222. **Список литературы**
 223. **Приложение**
 224. **Сводная таблица**
 225. **Выводы**
 226. **Рекомендации**
 227. **Заключение**
 228. **Список литературы**
 229. **Приложение**
 23



44/65




■■■■■ 9. TEP ■■■■ ■■ ■■■■ ■■■■
 ■■■■ ■■■■ (■■■■ ■■ ■■■■)

TEP ■■ ■■■■ ■■■■ ■■■■ ■■■■

■■■■ ■■■■ TEP ■■■■ ■■ ■■, ■■■ ■■■■ ■■■
 ■■■■ ■■■■ ■■■■ ■■■■ ■■■■ 'TEP ■■■■ ■■■■
 ■■■■ ■■■■ ' (■■■■ ■■■■, '■■ ■■■■ ■■■■
 ■■■■) ■■■■ ■■■■ | ■■■■ ■■■■ TEP
 ■■■■ ■■■■ ■■■■ ■■■■, ■■■ ■■ ■■■■ ■■■■
 ■■■■ ■■■■ ■■■■ ■■■■-■■■ ■■■■ ■■ ■■■■
 ■■■■ ■■ | ■■■■ ■■■■ ■■ ■■■■ ■■■■ ■■■■ ■■, ■■ ■■
 ■■■■ ■■■■ ■■, ■■■ ■■■■ ■■ | ■■■■ ■■■■
 ■■■■ ■■ ■■■■ ■■■■ |

1. ■■■■ TEP ■■■■ ■■■■ ■■■■ ■■■■ ■■■■
 16FR ■■■■ ■■■■ ■■■■ ■■■■ | ■■■■ ■■■■
 ■■■■ |
2. ■■■■ ■■ ■■■■ ■■■■ ■■■■ TEP ■■■■ ■■■■
 ■■■■, ■■■ ■■ ■■■■ ■■■■ 5 ■■■■ 6 ■■■■ (13 ■■■■ 15

[illegible]

10. TEP

3. [REDACTED]
[REDACTED] ([REDACTED] 11 [REDACTED]) | [REDACTED]
[REDACTED]-[REDACTED] [REDACTED] [REDACTED], [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] | [REDACTED]
TEP [REDACTED] TEP [REDACTED]
[REDACTED]

■■■■■ ■■■■■ ■■■■■■ ■■■■ ■■■■■ ■■■■■■■■■ ■■■■

[illegible]

A row of ten squares, each containing a number from 1 to 10. The numbers are: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.

[illegible]

_____ / _____

2020 年 12 月 31 日，本公司 2020 年度股东大会审议通过《关于 2020 年度利润分配预案的议案》，以 2020 年 12 月 31 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 1.00 元（含税），共计派发现金股利 10,000,000.00 元。该预案尚需 2021 年 6 月召开的 2020 年年度股东大会审议通过后方可实施。

■■■■■ ■■■■■

The first step in the process is to identify the problem. This involves gathering information about the issue and understanding the context in which it is occurring. Once the problem is identified, the next step is to analyze it. This involves breaking the problem down into its component parts and understanding how they are related to each other.

[illegible][illegible]

- $\frac{1}{2} \left(\frac{1}{2} + \frac{1}{2} \right) = 1$
- $\frac{1}{2} \left(\frac{1}{2} + \frac{1}{2} \right) = 1$
- TEP $\frac{1}{2} \left(\frac{1}{2} + \frac{1}{2} \right) = 1$

The cat sat on the mat and drank from the bowl.

The cat sat on the mat and drank from the bowl. (HME)

The cat sat on the mat and drank from the bowl. IHME

The cat sat on the mat and drank from the bowl. Provox

The cat sat on the mat and drank from the bowl. Provox Life Home HME

1. **Содержание**
 1.1. Общие сведения
 1.2. Назначение
 1.3. Технические характеристики
 1.4. Составные части
 1.5. Порядок эксплуатации
 1.6. Требования безопасности
 1.7. Техническое обслуживание
 1.8. Ремонт
 1.9. Гарантийные обязательства
 1.10. Контактная информация

- [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
- [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] 9:00 [REDACTED] [REDACTED] [REDACTED] 5:00
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] |

[REDACTED] 5:00 [REDACTED] [REDACTED] [REDACTED], [REDACTED]-[REDACTED] [REDACTED]
[REDACTED] [REDACTED], 212-639-2000 '[REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED], [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] |

[REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] | [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] |

[REDACTED]-[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED], [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] |

MSK [REDACTED] [REDACTED]

[REDACTED] [REDACTED]

212-639-7606

[REDACTED] [REDACTED] [REDACTED] [REDACTED], [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED], [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] |

[REDACTED] [REDACTED]

212-639-6840

[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED], [REDACTED] [REDACTED] [REDACTED] [REDACTED]
[REDACTED] [REDACTED] [REDACTED] |

■■■■ ■■■■ ■■■■

212-639-7643

■■ ■■■■ ■■ ■■■■ ■■ ■■ ■■■■■■■■ ■■, ■■ ■■■■ ■■■■
■■■ ■■■■■■■■■■ ■■■■ ■■■■ ■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■■■ |

■■■■■ ■■■■■■■■■■ ■■■■■■

www.msk.org/international

888-675-7722

■■■■ ■■■■■ ■■ ■■ ■■ ■■■■ ■■■■■■■■ ■■ ■■■■
■■■■ ■■ ■■ ■■■■■ ■■ ■■ ■■ ■■ ■■ ■■■■■■■■
■■■■■■ ■■■■ ■■ | ■■ ■■■■■ ■■■■■■■■■■■■■■■■■■■
■■, ■■■ ■■■■ ■■■■■■■ ■■ ■■■■ ■■■■ ■■■■■■■■■■
■■■ ■■ ■■ ■■ ■■■■■ ■■■■ ■■ |

■■■■■■■■■■ ■■■■■■

www.msk.org/counseling

646-888-0200

■■■■ ■■■■ ■■■■■ ■■ ■■■■ ■■ ■■ ■■■■■■■■■■
■■■■■ ■■ ■■ ■■■■ ■■ | ■■■■ ■■■■■■■■■■ ■■■■
■■■■■■■■, ■■■■■■, ■■■■■■■■■ ■■ ■■■■■ ■■ ■■■■
■■■■■■ ■■■■ ■■ | ■■ ■■■■■ ■■■■■ ■■ ■■■■
■■■■■■ ■■■■ ■■, ■■■ ■■■■ ■■■■■■■ ■■ ■■ ■■■■ ■■
■■■ ■■■■ ■■ | ■■■■ ■■■■■■■ ■■ ■■ ■■■■ ■■■■■
■■■ ■■■■■ ■■ ■■ ■■ ■■■■■■■■■■■ ■■ ■■ ■■■■
■■■■■ ■■■■, ■■ ■■ ■■ |

■■■ ■■■■■■■■ ■■■■■■■■

646-888-8055

■■■ ■■■■■ ■■ ■■■■ ■■■■■ ■■■■■ ■■■■■ ■■ ■■■■
■■■■■■ ■■■■■■■■■ ■■ | ■■■ ■■■■■■■ ■■ ■■■■
■■■■■■ ■■ ■■■■ ■■ ■■ ■■■■ ■■■■■ ■■ ■■ ■■
■■■ ■■■■ ■■■■■ ■■■■ ■■ ■■■■ ■■ |

■■■■■■■■■■■■■■ ■■■■■■ ■■■ ■■■■■■ ■■■■

www.msk.org/integrativemedicine

■■■■ ■■■■■■■■■■■■■ ■■■■■■ ■■ ■■■■■■ ■■■■

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We have a team of experts who can help you with your cancer journey. For more information, please call 646-449-1010.

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We have a team of experts who can help you with your cancer journey. For more information, please call 646-608-8550.

MSK

library.mskcc.org

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We have a team of experts who can help you with your cancer journey. For more information, please call 646-608-8550.

MSK

www.msk.org/nutrition

212-639-7312

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We have a team of experts who can help you with your cancer journey. For more information, please call 212-639-7312.

[illegible]

■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■

www.msk.org/pe

1. 2019年12月31日，公司资产总额为1,000,000,000.00元，负债总额为500,000,000.00元，所有者权益为500,000,000.00元。



646-227-3378

2020 年 12 月 31 日，本公司 2020 年度利润分配方案为：以 2020 年 12 月 31 日总股本 100,000,000 股为基数，向全体股东每 10 股派发现金股利 1.00 元（含税），共计派发现金股利 10,000,000.00 元。

[illegible]

212-639-7202

[illegible]

212-639-5935

[illegible]

646-357-9272

[illegible]

www.msk.org/rehabilitation

MSK's Cancer Support Community (CSC) provides a variety of resources to help patients and families navigate the cancer journey. CSC offers support groups, counseling, and educational programs. For more information, visit [csc.mskcc.org](#) or call 646-888-1900. CSC also provides a 24-hour helpline for emotional support and crisis intervention. For more information, visit [csc.mskcc.org](#) or call 646-888-1900.

- **MSK's Cancer Support Community (CSC)** provides a variety of resources to help patients and families navigate the cancer journey. CSC offers support groups, counseling, and educational programs. For more information, visit [csc.mskcc.org](#) or call 646-888-1900. CSC also provides a 24-hour helpline for emotional support and crisis intervention. For more information, visit [csc.mskcc.org](#) or call 646-888-1900.
- **MSK's Cancer Support Community (CSC)** provides a variety of resources to help patients and families navigate the cancer journey. CSC offers support groups, counseling, and educational programs. For more information, visit [csc.mskcc.org](#) or call 646-888-1900. CSC also provides a 24-hour helpline for emotional support and crisis intervention. For more information, visit [csc.mskcc.org](#) or call 646-888-1900.

MSK's Cancer Support Community (CSC) provides a variety of resources to help patients and families navigate the cancer journey. CSC offers support groups, counseling, and educational programs. For more information, visit [csc.mskcc.org](#) or call 646-888-1900. CSC also provides a 24-hour helpline for emotional support and crisis intervention. For more information, visit [csc.mskcc.org](#) or call 646-888-1900.

MSK's Cancer Support Community (CSC) provides a variety of resources to help patients and families navigate the cancer journey. CSC offers support groups, counseling, and educational programs. For more information, visit [csc.mskcc.org](#) or call 646-888-1900. CSC also provides a 24-hour helpline for emotional support and crisis intervention. For more information, visit [csc.mskcc.org](#) or call 646-888-1900.

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We are currently looking for a Social Worker to join our team. The ideal candidate will have a Master's degree in Social Work and be licensed in the state of New York. They will be responsible for providing emotional and social support to our patients and their families, as well as coordinating care with other members of the healthcare team. If you are interested in this position, please send your resume and cover letter to hr@msk.org.

MSK is an Equal Opportunity Employer. We are committed to creating a diverse and inclusive workplace. We encourage all qualified individuals to apply. For more information, please visit www.msk.org. MSK is a leading cancer center, and we are committed to providing the best care for our patients. We are currently looking for a Social Worker to join our team. The ideal candidate will have a Master's degree in Social Work and be licensed in the state of New York. They will be responsible for providing emotional and social support to our patients and their families, as well as coordinating care with other members of the healthcare team. If you are interested in this position, please send your resume and cover letter to hr@msk.org.

- MSK is a leading cancer center, and we are committed to providing the best care for our patients. We are currently looking for a Social Worker to join our team. The ideal candidate will have a Master's degree in Social Work and be licensed in the state of New York. They will be responsible for providing emotional and social support to our patients and their families, as well as coordinating care with other members of the healthcare team. If you are interested in this position, please send your resume and cover letter to hr@msk.org. MSK is an Equal Opportunity Employer. We are committed to creating a diverse and inclusive workplace. We encourage all qualified individuals to apply. For more information, please visit www.msk.org.
- MSK is a leading cancer center, and we are committed to providing the best care for our patients. We are currently looking for a Social Worker to join our team. The ideal candidate will have a Master's degree in Social Work and be licensed in the state of New York. They will be responsible for providing emotional and social support to our patients and their families, as well as coordinating care with other members of the healthcare team. If you are interested in this position, please send your resume and cover letter to hr@msk.org. MSK is an Equal Opportunity Employer. We are committed to creating a diverse and inclusive workplace. We encourage all qualified individuals to apply. For more information, please visit www.msk.org.

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We are currently looking for a Social Worker to join our team. The ideal candidate will have a Master's degree in Social Work and be licensed in the state of New York. They will be responsible for providing emotional and social support to our patients and their families, as well as coordinating care with other members of the healthcare team. If you are interested in this position, please send your resume and cover letter to hr@msk.org.

www.msk.org/socialwork

212-639-7020

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We are currently looking for a Social Worker to join our team. The ideal candidate will have a Master's degree in Social Work and be licensed in the state of New York. They will be responsible for providing emotional and social support to our patients and their families, as well as coordinating care with other members of the healthcare team. If you are interested in this position, please send your resume and cover letter to hr@msk.org. MSK is an Equal Opportunity Employer. We are committed to creating a diverse and inclusive workplace. We encourage all qualified individuals to apply. For more information, please visit www.msk.org.

MSK is a leading cancer center, and we are committed to providing the best care for our patients. We are currently looking for a Social Worker to join our team. The ideal candidate will have a Master's degree in Social Work and be licensed in the state of New York. They will be responsible for providing emotional and social support to our patients and their families, as well as coordinating care with other members of the healthcare team. If you are interested in this position, please send your resume and cover letter to hr@msk.org.

MSK's Cancer Center is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are also committed to advancing cancer research and improving the lives of patients through innovative therapies and clinical trials.

MSK's Cancer Center is a leading provider of cancer care and research.

212-639-5982

MSK's Cancer Center (MSKCC) is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are also committed to advancing cancer research and improving the lives of patients through innovative therapies and clinical trials.

MSK's Cancer Center (MSKCC) is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are also committed to advancing cancer research and improving the lives of patients through innovative therapies and clinical trials.

MSK's Cancer Center is a leading provider of cancer care and research.

www.msk.org/tobacco

212-610-0507

MSK's Cancer Center is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are also committed to advancing cancer research and improving the lives of patients through innovative therapies and clinical trials.

MSK's Cancer Center is a leading provider of cancer care and research.

www.msk.org/vp

MSK's Cancer Center is a leading provider of cancer care and research. We are committed to providing the best possible care for our patients. Our team of experts is dedicated to understanding the unique needs of each patient and providing personalized treatment plans. We are also committed to advancing cancer research and improving the lives of patients through innovative therapies and clinical trials.

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit. For more information, visit web.mta.info/nyct/paratran/guide.htm or call 877-337-2017.

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit. For more information, visit web.mta.info/nyct/paratran/guide.htm or call 877-337-2017.

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit.

877-337-2017

web.mta.info/nyct/paratran/guide.htm

877-337-2017

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit. For more information, visit web.mta.info/nyct/paratran/guide.htm or call 877-337-2017.

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit.

www.aircharitynetwork.org

877-621-7177

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit. For more information, visit web.mta.info/nyct/paratran/guide.htm or call 877-337-2017.

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit.

www.cancer.org

800-ACS-2345 (800-227-2345)

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit. For more information, visit web.mta.info/nyct/paratran/guide.htm or call 877-337-2017.

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit.

www.cancerandcareers.org

646-929-8032

MTA's Paratransit program provides accessible transportation for people with disabilities who are unable to use public transit. For more information, visit web.mta.info/nyct/paratran/guide.htm or call 877-337-2017.

[illegible]

www.healthwellfoundation.org

800-675-8416

[illegible]

www.joeshouse.org

877-563-7468

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 104

LGBT

www.lgbtcancer.com

[illegible][illegible]

www.livestrong.org/fertility

855-744-7777

■■■■■■■■ ■■■■■■■■ ■■■■■■■■■■ ■■■■ ■■■■■■■■ ■■■■ ■■■■ ■■
 ■■■■■■■■ ■■■■■■■■ ■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■
 ■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■ ■■, ■■■■■■■■■■ ■■ ■■■■■■■■■■ ■■■■■■■■
 ■■■■■■ ■■■■■■■■ ■■■■■■■■ ■■■■■■ ■■■■■■ ■■■■ ■■ ■■■■■■■■■■
 ■■■■■■■■■■■■■■ ■■■ ■■■■■■■■ ■■■■ |

www.health.ny.gov/health_care/medicaid/program/pharmacy.htm

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

www.panfoundation.org

866-316-7263

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

www.patientadvocate.org

800-532-5274

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

www.reddoorcommunity.org

212-647-9700

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

RxHope

www.rxhope.com

877-267-0517

For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm. For more information on Medicaid pharmacy services, visit the New York State Department of Health website at www.health.ny.gov/health_care/medicaid/program/pharmacy.htm.

[care/patient-education/mymsk-recovery-tracker\)](#)

- *Advance Care Planning for People With Cancer and Their Loved Ones* ([www.mskcc.org/cancer-care/patient-education/advance-care-planning](#))
- *How To Check if a Medicine or Supplement Has Aspirin, Other NSAIDs, Vitamin E, or Fish Oil* ([www.mskcc.org/cancer-care/patient-education/common-medications-containing-aspirin-and-other-nonsteroidal-anti-inflammatory-drugs-nsaids](#))
- *Herbal Remedies and Cancer Treatment* ([www.mskcc.org/cancer-care/patient-education/herbal-remedies-and-treatment](#))
- *How to Be a Health Care Agent* ([www.mskcc.org/cancer-care/patient-education/how-be-health-care-agent](#))
- *Patient-Controlled Analgesia (PCA)* ([www.mskcc.org/cancer-care/patient-education/patient-controlled-analgesia-pca](#))

MSKCC is a leading cancer center in New York City. We are committed to providing the best care for our patients. Our team of experts includes surgeons, medical oncologists, radiation oncologists, and other specialists. We offer a wide range of treatment options, including surgery, chemotherapy, and radiation therapy. Our goal is to help our patients live longer and better lives. For more information, please contact us at 212-639-2000 or visit our website at [www.mskcc.org](#).

MSKCC is a leading cancer center in New York City. We are committed to providing the best care for our patients. Our team of experts includes surgeons, medical oncologists, radiation oncologists, and other specialists. We offer a wide range of treatment options, including surgery, chemotherapy, and radiation therapy. Our goal is to help our patients live longer and better lives. For more information, please contact us at 212-639-2000 or visit our website at [www.mskcc.org](#).

About Your Total Laryngectomy - Last updated on March 31, 2026

MSKCC is a leading cancer center in New York City. We are committed to providing the best care for our patients. Our team of experts includes surgeons, medical oncologists, radiation oncologists, and other specialists. We offer a wide range of treatment options, including surgery, chemotherapy, and radiation therapy. Our goal is to help our patients live longer and better lives. For more information, please contact us at 212-639-2000 or visit our website at [www.mskcc.org](#).